GriegerJC, SoltysSM, SamulskiRJ. Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Mol Ther, 2016; 24:287–297.
2.
AalbersCJ, BroekstraN, van GeldorpM, et al.Empty capsids and macrophage inhibition/depletion increase rAAV transgene expression in joints of both healthy and arthritic mice. Hum Gene Ther, 2016Nov2 [Epub ahead of print].
3.
MingozziF, AnguelaXM, PavaniG, et al.Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med, 2013; 5:194ra92.
4.
WrightJF. AAV empty capsids: for better or for worse?. Mol Ther, 2014; 22:1–2.
5.
TreanorJJ, El SahlyH, KingJ, et al.Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine, 2011; 29:7733–7739.
6.
BaxterR, PatriarcaPA, EnsorK, et al.Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age. Vaccine, 2011; 29:2272–2278.
